According to a market report, published by Sheer Analytics and Insights, The global atrial fibrillation surgery market was valued at $1.81 billion in 2021 and it is expected to reach $7.8 billion at a CAGR of 13.4% between 2022 and 2032. The most prevalent form of arrhythmia that results in an irregular and frequently rapid heartbeat is called atrial fibrillation (AF). Atrial fibrillation cases have increased in frequency globally over the past 20 years. Additionally, the global increase in obesity and cardiac problems is a major driver of the atrial fibrillation industry. Additionally, cardiac illnesses are one of the leading causes of death worldwide, and their prevalence is increasing quickly as a result of changing lifestyles. Treatment for irregular heartbeats that start in the upper chambers of the heart includes atrial fibrillation (atria). It is a type of cardiac ablation that stops the erroneous electrical signals that lead to arrhythmia by scarring or damaging the heart's tissue. During the forecast period of 2022 to 2032, it is anticipated that the market will experience significant growth opportunities due to the quick development of technology, an increase in the number of surgical and catheter ablation procedures for atrial fibrillation, and a rise in the number of applications from emerging economies. These primary factors are driving the market growth.
However, the global increase in obesity and cardiac disorders is a major driver of the atrial fibrillation industry. Additionally, cardiac illnesses are one of the leading causes of death worldwide, and their prevalence is increasing quickly as a result of changing lifestyles. Additionally, the industry will benefit from the growing research and development initiatives highlighting the developments in the atrial fibrillation market. For instance, Peer bridge Health and North well Health worked together to develop their AFib Center of Excellence in January 2022. This multidisciplinary initiative aims to improve the care of patients with atrial fibrillation (AFib). These are estimated to create more growth opportunities for the market in the future.
Request a Sample Copy of Report: https://www.sheeranalyticsandinsights.com/request-sample/atrial-fibrillation-surgery-market-21
Furthermore, combination pharmaceutical therapy is a brand-new and optimistic atrial fibrillation treatment option. In clinical trials, the combined pharmacological therapy showed positive outcomes and would assist meet the unmet medical needs of patients with atrial fibrillation. The atrial fibrillation market is expected to be driven by this reason globally. Additionally, research on combined therapy in an animal model produced positive and effective anti-arrhythmic outcomes.
On the other hand, the aforementioned factors would likely cause the market under study to expand over the predicted period. However, it is anticipated that the high cost of treatments and regulatory concerns related to these devices will impede market expansion. It is projected that expansion will be constrained by the dearth of qualified cardiac surgeons in several developing and underdeveloped areas who are competent in carrying out such surgical treatments. Even though atrial fibrillations are becoming more common, there are now fewer doctors than there are patients, due to poor governmental and private investments in the healthcare industry.
According to the study, key players dominating the global atrial fibrillation surgery market are Abbott Laboratories (U.S), Acutus Medical (U.S), Atricure (U.S), Biomerics (U.S), Biotronik (Germany), Boston Scientific (U.S), CardioFocus (U.S), EP Solutions (Switzerland), General Electronic (U.S), Japan Lifeline (Japan), Johnson & Johnson (U.S), Microsoft (U.S), Merit Medical Systems (U.S), Medtronic (Ireland), Sanofi (France), Siemens (Germany), Teleflex (U.S), among others.
The Global Atrial Fibrillation Surgery Market – by Product Type:
The Global Atrial Fibrillation Surgery Market – by Surgery Type:
The Global Atrial Fibrillation Surgery Market – by Regions:
North America
Europe
Asia-Pacific
LAMEA
Browse the full report at https://www.sheeranalyticsandinsights.com/market-report-research/atrial-fibrillation-surgery-market-21
About Us
Sheer Analytics and Insights Private Limited is market research, consulting, and IT services company. We as a company believe in providing point to point data and its analysis with the combination of our human and automation integration. Sheer Analytics and Insights cover majorly eight industry verticals, including chemicals, life science, communications, and electronics, materials, consumer goods, defense, and BFSI sector.
Sheer Analytics believes in quality work and ensures that the product delivered to the client is meaningful for them. We publish reports based on our advanced analytics reports, which are generated with the help of our in-house databases, external databases, and artificial intelligence integration processes. We stand out from other market research companies in terms of integrating facts with meaningful insights for forecasting.
Contact:
Sheer Analytics and Insights
Email: sales@sheeranalyticsandinsights.com
Email: query@sheeranalyticsandinsights.com
Call Us:- +1-414-240-5010